Novadaq Technologies Inc (NASDAQ:NVDQ) (TSE:NDQ)‘s stock had its “hold” rating reaffirmed by Northland Securities in a research report issued to clients and investors on Monday. They currently have a $11.75 target price on the medical research company’s stock. Northland Securities’ target price indicates a potential upside of 95.83% from the stock’s previous close.

Several other equities research analysts also recently commented on NVDQ. Royal Bank Of Canada set a $12.00 target price on Novadaq Technologies and gave the company a “buy” rating in a report on Wednesday, March 1st. Canaccord Genuity reaffirmed a “buy” rating and set a $10.00 target price on shares of Novadaq Technologies in a report on Wednesday, February 22nd. Feltl & Co. downgraded Novadaq Technologies from a “buy” rating to a “hold” rating in a report on Wednesday, March 1st. Zacks Investment Research downgraded Novadaq Technologies from a “hold” rating to a “strong sell” rating in a report on Saturday, March 4th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $10.00 target price on shares of Novadaq Technologies in a report on Friday, June 2nd. Five investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Novadaq Technologies currently has an average rating of “Buy” and an average target price of $11.84.

Analyst Recommendations for Novadaq Technologies (NASDAQ:NVDQ)

Novadaq Technologies (NASDAQ:NVDQ) traded up 96.83% during mid-day trading on Monday, reaching $11.81. The company had a trading volume of 18,084,806 shares. Novadaq Technologies has a 12 month low of $5.84 and a 12 month high of $12.74. The stock’s 50-day moving average is $7.04 and its 200 day moving average is $7.19. The firm’s market capitalization is $682.64 million.

Novadaq Technologies (NASDAQ:NVDQ) (TSE:NDQ) last announced its quarterly earnings data on Wednesday, May 3rd. The medical research company reported ($0.24) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by $0.03. Novadaq Technologies had a negative net margin of 71.97% and a negative return on equity of 49.93%. The firm had revenue of $21.08 million during the quarter, compared to analyst estimates of $20.12 million. On average, analysts predict that Novadaq Technologies will post ($0.80) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/06/19/novadaq-technologies-inc-nvdq-receives-hold-rating-from-northland-securities.html.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. US Bancorp DE raised its position in Novadaq Technologies by 0.8% in the first quarter. US Bancorp DE now owns 46,899 shares of the medical research company’s stock valued at $365,000 after buying an additional 362 shares during the last quarter. State Street Corp raised its position in Novadaq Technologies by 4.5% in the fourth quarter. State Street Corp now owns 26,164 shares of the medical research company’s stock valued at $186,000 after buying an additional 1,138 shares during the last quarter. Geode Capital Management LLC raised its position in Novadaq Technologies by 8.2% in the first quarter. Geode Capital Management LLC now owns 29,004 shares of the medical research company’s stock valued at $225,000 after buying an additional 2,194 shares during the last quarter. Envestnet Asset Management Inc. raised its position in Novadaq Technologies by 12.9% in the first quarter. Envestnet Asset Management Inc. now owns 25,374 shares of the medical research company’s stock valued at $197,000 after buying an additional 2,898 shares during the last quarter. Finally, Clearbridge Investments LLC raised its position in Novadaq Technologies by 0.4% in the first quarter. Clearbridge Investments LLC now owns 2,554,843 shares of the medical research company’s stock valued at $19,902,000 after buying an additional 9,371 shares during the last quarter. 88.25% of the stock is currently owned by hedge funds and other institutional investors.

About Novadaq Technologies

NOVADAQ Technologies Inc is a medical device company. The Company primarily develops, manufactures and markets real-time fluorescence imaging products that are designed for use by surgeons in the operating room and other clinical settings where open and minimally invasive surgery or interventional procedures are performed.

Receive News & Ratings for Novadaq Technologies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novadaq Technologies Inc and related companies with MarketBeat.com's FREE daily email newsletter.